Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases.
References:
[1]. Anderson, et al. Preparation of substituted pyrrolopyridine compounds as JAK inhibitors. World Intellectual Property Organization, WO2019090158 A1 2019-05-09.
















